Core Viewpoint - Microelectrophysiology reported a decline in stock price on August 26, closing at 25.18 yuan, down 2.55% from the previous trading day, with a trading volume of 1.97 billion yuan [1] Company Summary - Microelectrophysiology operates in the medical device industry, focusing on the research, production, and sales of cardiac electrophysiology interventional diagnostic devices [1] - The company's main products include a three-dimensional cardiac electrophysiology mapping system and cardiac radiofrequency ablation catheters [1] - In the first half of 2025, the company achieved operating revenue of 224 million yuan, representing a year-on-year growth of 12.80%, and a net profit attributable to shareholders of 32.67 million yuan, up 92.02% year-on-year [1] - The growth in performance is attributed to an expansion in sales scale and effective cost reduction measures [1] - On the same day, the company announced the appointment of Lin Yishan as the securities affairs representative [1] Market Activity - On August 26, the net inflow of main funds into Microelectrophysiology was 1.59 million yuan, while the cumulative net outflow over the past five trading days reached 26.79 million yuan [1]

Group 1 - The supervisory board of Shanghai MicroPort CardioFlow Medtech Corp. held its 16th meeting of the third session on August 26, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1][2] - The supervisory board approved the company's 2025 semi-annual report, stating that it accurately reflects the company's operational status without any false records or omissions [1][2] - The board confirmed that the company has managed and used raised funds in accordance with regulations, ensuring no harm to shareholder interests [2][3] Group 2 - The supervisory board agreed to use part of the temporarily idle raised funds for cash management, which is expected to enhance fund efficiency without affecting normal operations or investment projects [2][3] - The decision to manage idle funds was unanimously supported by the supervisory board, with all votes in favor [2][3]

Core Viewpoint - The company plans to utilize temporarily idle raised funds (including oversubscription funds) for cash management, with an investment amount of up to 650 million yuan, focusing on high-safety and liquid financial products [1][4][6]. Fundraising Basic Situation - The company raised a total of 1,165.606 million yuan from the public offering of 70.6 million shares at a price of 16.51 yuan per share, with a net amount of 1,069.8799 million yuan after deducting issuance costs [2]. - The actual funds were received on August 25, 2022, and have been verified by an accounting firm [2]. Previous Cash Management - In August 2024, the company approved the use of up to 750 million yuan of temporarily idle raised funds for cash management, with the authorization period ending on August 19, 2025 [3][4]. Current Cash Management Situation - The purpose of using idle funds is to enhance the efficiency of fund utilization without affecting the normal operation of investment projects [4][6]. - The company intends to invest in safe and liquid products, including structured deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [4][5]. - The cash management amount is capped at 650 million yuan, with a validity period of 12 months from the board's approval [4][5]. Impact on Daily Operations - The cash management will not affect the company's main business operations and aims to improve the efficiency of fund usage, benefiting the company and all shareholders [5][6]. Risk Control Measures - The company will select high-safety and liquid cash management products and will monitor market conditions to manage investment risks [6][7]. Decision-Making Procedures - The board and supervisory board approved the cash management proposal on August 26, 2025, ensuring compliance with relevant laws and regulations [7][8].

Core Viewpoint - Shanghai MicroPort EP Medical Technology Co., Ltd. has appointed Ms. Lin Yishan as the securities affairs representative to assist the board secretary in daily operations, effective from the date of the board meeting on August 26, 2025 [1][2] Group 1: Appointment Details - The board of directors approved the appointment of Ms. Lin Yishan as the securities affairs representative [1] - Ms. Lin holds a qualification certificate from the Shanghai Stock Exchange for board secretaries and possesses the necessary professional knowledge and capabilities for the role [1][2] - Her term will last until the end of the current board's tenure [1] Group 2: Ms. Lin Yishan's Background - Ms. Lin was born in November 1993, is a Chinese national, and does not hold permanent residency abroad [2] - She has a master's degree and joined the company in 2024 [2] - As of the announcement date, she does not hold any shares in the company and has no relationships with major shareholders or company executives [2]

证券代码：688351 证券简称：微电生理 公告编号：2025-018 上海微创电生理医疗科技股份有限公司 关于 2025 年度"提质增效重回报" 行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为落实国务院《关于加强监管防范风险推动资本市场高质量发展的若干意 见》《关于进一步提高上市公司质量的意见》相关要求，践行"以投资者为本" 的发展理念，进一步提高公司经营质量，增强投资者回报信心，提升投资者获得 感，上海微创电生理医疗科技股份有限公司（以下简称"公司"）制定了《2025 年度"提质增效重回报"行动方案》，并于 2025 年 8 月 26 日召开第三届董事会 第十六次会议审议通过了该方案。方案内容具体如下： 一、深耕电生理领域，提升核心竞争力 公司以研发和提供心脏电生理介入诊疗领域的完整解决方案为核心，持续推 动技术创新，是全球少数同时拥有电生理设备和耗材全产品线生产能力的厂商。 依托多年技术积累，公司攻克了三维磁电双定位技术、磁导航定位等关键技术， 成为国内首个实现三维电生理设备和耗材全面布局的企业。 ...

Core Viewpoint - The company has successfully raised a total of RMB 106,987.99 million through its public offering, with a net amount of RMB 106,987.99 million after deducting issuance costs, and has established a structured management system for the use of these funds [1][3]. Fundraising Overview - The company issued 70.6 million shares at a price of RMB 16.51 per share, resulting in total fundraising of RMB 116,560.60 million [1]. - After deducting issuance costs of RMB 9,572.61 million, the actual net amount raised was RMB 106,987.99 million [1]. Fund Management - The company has implemented a dedicated fund management system in compliance with relevant laws and regulations, ensuring the protection of investor rights [1]. - A tripartite supervision agreement for fund storage was signed with several banks to regulate the management and use of the raised funds [1]. Fund Usage Status - As of June 30, 2025, the company has invested a total of RMB 476,090,539.82 in fundraising projects [3]. - The remaining balance of the raised funds is RMB 643,049,108.16, with RMB 479,049,108.16 stored in dedicated bank accounts and RMB 164,000,000.00 invested in bank financial products [3]. Specific Project Investments - The company has allocated funds to various projects, including RMB 23,706,690.90 for the development of electrophysiological intervention medical devices and RMB 27,694,669.79 for the marketing service system [3]. - The company has not engaged in any prior investment or replacement of raised funds during the reporting period [3]. Changes in Fund Usage - The company has approved changes and delays in certain fundraising investment projects to enhance the effectiveness of fund usage based on operational needs [3][6]. - The company has also utilized part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for project implementation [3][6].

Core Viewpoint - The company plans to reappoint Lixin Certified Public Accountants (Special General Partnership) as its auditing firm for the fiscal year 2025, pending approval from the shareholders' meeting [1]. Group 1: Auditor Information - Lixin Certified Public Accountants was founded in 1927 by Dr. Pan Xulun and is a member of the international accounting network BDO [1]. - As of the end of 2024, Lixin has 296 partners, 2,498 registered accountants, and a total of 10,021 employees [2]. - Lixin has a professional risk fund of 171 million yuan and a cumulative insurance coverage limit of 1.05 billion yuan for professional liability [2]. Group 2: Legal and Regulatory History - Lixin has faced five administrative penalties and 43 supervisory measures in the past three years, with no criminal penalties [5]. - The firm has been involved in civil lawsuits related to securities false statements, with judgments requiring Lixin to cover a portion of compensation liabilities [4][5]. Group 3: Audit Project Information - The audit fee for the fiscal year 2024 is set at 700,000 yuan, with internal control audit fees at 50,000 yuan [6]. - The audit committee has reviewed Lixin's professional competence and independence, recommending its reappointment [7]. Group 4: Approval Process - The board of directors approved the reappointment of Lixin on August 26, 2025, and will submit the decision to the shareholders' meeting for final approval [7].

Core Viewpoint - The company is utilizing temporarily idle raised funds for cash management to enhance fund efficiency while ensuring that it does not affect the normal operation of its investment projects [1][8][12]. Fundraising Basic Information - The company raised a total of RMB 1,069,879,920.88 by issuing 70.6 million shares at a price of RMB 16.51 per share, with the funds received on August 25, 2022 [1][2]. Fund Management Agreements - The company and its subsidiary signed agreements with the sponsor and the bank to establish a special account for the management of raised funds, ensuring proper storage and management [2]. Investment Project Overview - The total investment amount for the projects funded by the raised capital is RMB 101,182.57 million [3]. Previous Cash Management - The company approved the use of up to RMB 75,000 million of temporarily idle funds for cash management, with a validity period of 12 months from the board's approval [3][4]. Current Cash Management Plan - The company plans to use up to RMB 65,000 million of temporarily idle funds for cash management, focusing on high-security and liquid investment products [7][8]. Impact on Daily Operations - The cash management will not affect the company's main business operations and aims to improve the efficiency of fund usage, benefiting the company and its shareholders [8][12]. Decision-Making Process - The board and supervisory board approved the cash management plan, ensuring compliance with relevant laws and regulations [11][12]. Sponsor's Opinion - The sponsor has no objections to the cash management plan, confirming that it complies with regulatory requirements and does not alter the purpose of the raised funds [12][13].

每经AI快讯，微电生理（SH 688351，收盘价：25.18元）8月26日晚间发布公告称，公司审议通过了 《关于聘任证券事务代表的议案》，同意聘任林艺珊女士为公司证券事务代表，协助董事会秘书开展日 常工作。 （记者 王晓波） 2024年1至12月份，微电生理的营业收入构成为：医疗器械占比98.48%，其他业务占比1.52%。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 截至发稿，微电生理市值为118亿元。 ...

核查意见 华泰联合证券有限责任公司关于 上海微创电生理医疗科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作 为上海微创电生理医疗科技股份有限公司（以下简称"微电生理"或"公司"） 首次公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上 市保荐业务管理办法》《科创板上市公司持续监管办法（试行）》《上海证券交 易所科创板股票上市规则（2025 年 4 月修订）》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》《上市公司募集 资金监管规则》等相关法律、法规和规范性文件的规定，对微电生理使用部分暂 时闲置募集资金（含超募资金）进行现金管理的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2022]1587 号文《关于同意上海微创电 生理医疗科技股份有限公司首次公开发行股票注册的批复》，并经上海证券交易 所同意，公司于 2022 年 8 月 19 日向社会公众公开发行普通股（A 股）股票 7,060.00 万股，每股面值 1 元，每股发行 ...